Fig. 4.

Outline of the lipidomic alterations in liver cancer progression.

Progression from the normal liver through chronic liver disease (hepatic steatosis to NASH) and into primary liver cancers. Oncogenic pathways activated by a change in different metabolic classes (SFA; MUFA; S1P; TG; BA; Chol) during neoplastic onset. Activation of DNL and p53-mediated inactivation of FAO. BA, bile acid; Chol, cholesterol; DNL, de novo lipogenesis; FAO, fatty acid oxidation; MUFA, monounsaturated fatty acid; NASH, non-alcoholic steatohepatitis; S1P, sphingosine-1-phosphate; SFA, saturated fatty acid; TG, triglyceride.